180 Life Sciences Corp. announced that the United States Patent and Trademark Office has issued the Company a Notice of Allowance for United States (US) patent application number 17/721,106 entitled “Method of Treating Dupuytren's disease Using a Pre-filled Syringe”, which includes claims relating to the use of a citrate-free formulation of 40mg in 0.4mL of adalimumab to be injected into nodules of early-stage Dupuytren's disease every 3 months over a period of 12 months using a syringe with a 25 gauge needle. This reflects the dosage and method used in the RIDD trial led by Professor Nanchahal and his colleagues at the University of Oxford, the results of which were published in The Lancet Rheumatology.

A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application. A patent from the recently allowed application is expected to be issued in the coming months. The issued patent would have a term that expires no earlier than in 2037.

With the addition of this potential patent, the patent portfolio of 180 Life Sciences will have twelve issued patents and twelve pending patent applications within the US. Outside of the US, assuming the EU as a single jurisdiction and including the UK, there are an additional twelve issued patents and 21 pending patent applications.